A cross‑sectional analysis found that few registration trials assessing immune checkpoint inhibitors (ICIs) cancer therapies report long-term overall survival data. Among nearly 90 FDA-approved ICIs indications in the metastatic setting, less than one third of trials had overall survival data at 3 years, and even fewer (about 11%) reported overall survival data at 5 years.

Most registration trials for ICI cancer therapies don’t report long term overall survival data, a cross-sectional analysis finds.